Home Featured Page 165

Featured

Latest

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

MindMed Reports Full Year 2021 Financial Results and Business Highlights

MindMed Announces Transition of CFO

Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

Nova Mentis Begins Enrollment in North American Autism Study

Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing...

Psyched Wellness and the National Research Council of Canada Announce Preliminary...

Cybin Announces Additional Adelia Milestone Achievement

PT304 – Jerry B. Brown, Ph.D. – Vital Psychedelic Conversations

Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

Filament Health Announces Second Patent Issuance

1...164165166...291 Page 165 of 291

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

MindMed Reports Full Year 2021 Financial Results and Business Highlights

MindMed Announces Transition of CFO

Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

Nova Mentis Begins Enrollment in North American Autism Study

Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing...

Psyched Wellness and the National Research Council of Canada Announce Preliminary...

Cybin Announces Additional Adelia Milestone Achievement

PT304 – Jerry B. Brown, Ph.D. – Vital Psychedelic Conversations

Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

Filament Health Announces Second Patent Issuance

EDITOR PICKS

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY